Clinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsia

Proportion of patients with each educational status (higher, secondary special, secondary general);

To achieve the primary objectives of the study the following baseline clinical and demographic characteristics of patients will be collected or evaluated. The term 'baseline' means that the data is obtained at the inclusion into the study (Visit 1) during retrospective data collection from patient medical documentation or via interview with a patient on Visit 1, where applicable.

Time frame: Day 0 (Visit 1)

Proportion of patients from each residential region (federal district of Russia);

To achieve the primary objectives of the study the following baseline clinical and demographic characteristics of patients will be collected or evaluated. The term 'baseline' means that the data is obtained at the inclusion into the study (Visit 1) during retrospective data collection from patient medical documentation or via interview with a patient on Visit 1, where applicable.

Time frame: Day 0 (Visit 1)

Other than PN specific NF1 symptoms and manifestations

skin symptoms and manifestations, tumor manifestations (except malignancies), neurological and cognitive manifestations, cardiovascular manifestations, endocrine manifestations, orthopedic manifestations (distinctive osseous lesions), ophthalmological manifestations, NF1 mutation, presence of NF1 diagnostic criteria in one of parents) (frequency distribution at baseline)

Time frame: Day 0 (Visit 1)

NF1-associated complications

malignancy, hypertension, vasculopathy, bone symptoms, chronic neurological conditions, neuropathy, and pain

Time frame: Day 0 (Visit 1)

Non-specific NF1-comorbidities, coded by MedDRA system organ class (SOC) and preferred term (PT)

To achieve the primary objectives of the study the following baseline clinical and demographic characteristics of patients will be collected or evaluated. The term 'baseline' means that the data is obtained at the inclusion into the study (Visit 1) during retrospective data collection from patient medical documentation or via interview with a patient on Visit 1, where applicable.

Time frame: Day 0 (Visit 1)

Proportion of patients with various specific and non-specific NF1-comorbidities

To achieve the primary objectives of the study the following baseline clinical and demographic characteristics of patients will be collected or evaluated. The term 'baseline' means that the data is obtained at the inclusion into the study (Visit 1) during retrospective data collection from patient medical documentation or via interview with a patient on Visit 1, where applicable.

Time frame: Day 0 (Visit 1)

Proportion of patients with various PN-associated symptoms

To achieve the primary objectives of the study the following baseline clinical and demographic characteristics of patients will be collected or evaluated. The term 'baseline' means that the data is obtained at the inclusion into the study (Visit 1) during retrospective data collection from patient medical documentation or via interview with a patient on Visit 1, where applicable.

Time frame: Day 0 (Visit 1)

Proportion of patients with various ECOG score

To achieve the primary objectives of the study the following baseline clinical and demographic characteristics of patients will be collected or evaluated. The term 'baseline' means that the data is obtained at the inclusion into the study (Visit 1) during retrospective data collection from patient medical documentation or via interview with a patient on Visit 1, where applicable.

Time frame: Day 0 (Visit 1)

Proportion of patients with various PN locations

To achieve the primary objectives of the study the following baseline clinical and demographic characteristics of patients will be collected or evaluated. The term 'baseline' means that the data is obtained at the inclusion into the study (Visit 1) during retrospective data collection from patient medical documentation or via interview with a patient on Visit 1, where applicable.

Time frame: Day 0 (Visit 1)

PN volume (established by MRI)

To achieve the primary objectives of the study the following baseline clinical and demographic characteristics of patients will be collected or evaluated. The term 'baseline' means that the data is obtained at the inclusion into the study (Visit 1) during retrospective data collection from patient medical documentation or via interview with a patient on Visit 1, where applicable.

Time frame: Day 0 (Visit 1)

Duration of PN symptoms persistence before inclusion into the study

to be calculated between the date when initially symptoms of PN appeared and the date of Visit 1

Time frame: Day 0 (Visit 1)

Duration of PN diagnosis before inclusion into the study

to be calculated between the date of primary diagnosis of PN and the date of Visit 1

Time frame: Day 0 (Visit 1)

Medical history of PN

size, symptoms, previous medical interventions, surgeries or treatments

Time frame: Day 0 (Visit 1)

Previous physical, instrumental and laboratory examination results

To achieve the primary objectives of the study the following baseline clinical and demographic characteristics of patients will be collected or evaluated. The term 'baseline' means that the data is obtained at the inclusion into the study (Visit 1) during retrospective data collection from patient medical documentation or via interview with a patient on Visit 1, where applicable.

Time frame: Day 0 (Visit 1)

Amount and duration of hospitalizations associated with NF1 according to the investigator's opinion, collected from the medical history since the date of NF1 diagnosis

if applicable, to be calculated in patients with at least one such hospitalization

Time frame: Day 0 (Visit 1)

Degree of disability at baseline

if applicable, to be calculated in patients with presence of disability at Visit 1

Time frame: Day 0 (Visit 1)

Changing in disability degree during the study

if applicable, to be calculated in patients with presence of disability at Visit 1

Time frame: Day 0 (Visit 1)